☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
201 Study
Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer's Disease at CTAD 2021
November 12, 2021
Biogen and Eisai Report Results of Lecanemab (BAN2401) in P-IIb Study 201 for Patients with Early Alzheimer Disease
April 20, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.